Redhill Biopharma Ltd. (NASDAQ:RDHL) Stock Short Interest Declines 52.3%

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 61,151 shares, a decrease of 52.3% from the October 15th total of 128,328 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily volume of 132,590 shares, the short-interest ratio is currently 0.5 days.

Redhill Biopharma Trading Down 1.6%

RDHL traded down $0.01 during midday trading on Friday, hitting $0.38. The company had a trading volume of 35,193 shares, compared to its average volume of 106,631. Redhill Biopharma has a twelve month low of $0.36 and a twelve month high of $1.60. The firm’s 50-day simple moving average is $0.50 and its 200-day simple moving average is $0.77.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL. RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults.